/JNCE

JNCE Stock - Jounce Therapeutics, Inc.

Q: What is the analyst price target for JNCE?

Analyst price target information is not currently available for JNCE.

Q: What is JNCE's market cap?

Market capitalization information is not currently available for JNCE.

Healthcare|Biotechnology|NASDAQ

$1.88+0.00%

+$0.00 (+0.00%) • May 3

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $2.07

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for JNCE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2018

FY2019

FY2020

FY2021

FY2022

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.75

52W High$5.37

52W Low$0.58

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2022	FY2021	FY2020	FY2019	FY2018
Revenue	$82.00M	$26.91M	$62.34M	$147.87M	$65.20M
Gross Profit	$82.00M	$26.91M	$62.34M	$147.87M	$65.20M
Gross Margin	100.0%	100.0%	100.0%	100.0%	100.0%
Operating Income	$-52,242,000	$-91,056,000	$-45,117,000	$52.82M	$-31,294,000
Net Income	$-50,919,000	$-90,872,000	$-43,842,000	$56.82M	$-27,379,000
Net Margin	-62.1%	-337.7%	-70.3%	38.4%	-42.0%
EPS	$-0.99	$-1.82	$-1.24	$1.72	$-0.84

Company Overview

Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Visit Website

Rating Distribution

Strong Buy

50%

Buy / Outperform

Hold / Neutral

50%

Sell / Underperform

Analyst Consensus🟡 Mixed

1 Bullish1 Neutral/Bearish

Price Targets

$14

Average Target

↑ 618.1% Upside

Now

Low

$14

Average

$20

High

Based on 2 analysts

Recent Analyst Actions

Date	Firm	Action	Rating	Price Target
May 11th 2022	Robert W. Baird	Downgrade	Neutral	$7← $15
May 6th 2022	Raymond James	Upgrade	Strong Buy	$20← $15

Earnings History & Surprises

JNCE

Beat Rate

38%

Last 13 quarters

Avg Surprise

-11.4%

EPS vs Estimate

Beats / Misses

5/7

1 met exactly

Latest EPS

$-0.72

Q2 2023

EPS Surprise History

Q3 21

+78.9%

$-0.08vs$-0.38

Q4 21

-47.5%

$-0.59vs$-0.40

Q4 21

No data

Q2 22

-26.3%

$-0.72vs$-0.57

Q3 22

+4.4%

$-0.65vs$-0.68

Q4 22

+6.3%

$-0.60vs$-0.64

Q4 22

No data

Q2 23

0.0%

$-0.72vs$-0.72

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2024	Mar 8, 2024	—	—	—	—
Q4 2023	Nov 8, 2023	—	—	—	—
Q3 2023	Aug 2, 2023	$-0.68	—	—	—
Q2 2023	May 4, 2023	$-0.72	$-0.72	0.0%	= MET
Q4 2022	Dec 31, 2022	—	$0.99	—	—
Q4 2022	Nov 10, 2022	$-0.64	$-0.60	+6.3%	✓ BEAT
Q3 2022	Aug 4, 2022	$-0.68	$-0.65	+4.4%	✓ BEAT
Q2 2022	May 5, 2022	$-0.57	$-0.72	-26.3%	✗ MISS
Q4 2021	Dec 31, 2021	—	$0.00	—	—
Q4 2021	Nov 4, 2021	$-0.40	$-0.59	-47.5%	✗ MISS
Q3 2021	Aug 5, 2021	$-0.38	$-0.08	+78.9%	✓ BEAT
Q2 2021	May 4, 2021	$-0.37	$-0.58	-56.8%	✗ MISS
Q4 2020	Dec 31, 2020	—	$0.86	—	—
Q4 2020	Nov 6, 2020	$-0.37	$-0.73	-97.3%	✗ MISS
Q3 2020	Aug 7, 2020	$-0.72	$-0.82	-13.9%	✗ MISS
Q2 2020	May 6, 2020	$-0.64	$-0.78	-21.9%	✗ MISS
Q4 2019	Dec 31, 2019	—	$-0.68	—	—
Q4 2019	Nov 7, 2019	$2.24	$2.90	+29.5%	✓ BEAT
Q3 2019	Aug 7, 2019	$-0.26	$-0.21	+19.2%	✓ BEAT
Q2 2019	May 8, 2019	$-0.31	$-0.38	-22.6%	✗ MISS

Frequently Asked Questions about JNCE

What is JNCE's current stock price?

Jounce Therapeutics, Inc. (JNCE) is currently trading at $1.88 per share. The stock has moved +0.00% today.

What is the analyst price target for JNCE?

No analyst price targets are currently available for this stock.

What sector is Jounce Therapeutics, Inc. in?

Jounce Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is JNCE's market cap?

Jounce Therapeutics, Inc. has a market capitalization of $0.10 billion, making it a small-cap company.

Does JNCE pay dividends?

No, Jounce Therapeutics, Inc. does not currently pay a dividend to shareholders.